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1. Introduction 
Spinal cord injury (SCI) is a devastating clinical problem that has irreversible consequences, 
results in permanent functional loss, and life time disability (Sekhon and Fehlings, 2001). 
This debilitating condition often affects young and healthy individuals at the prime of their 
life, creates enormous physical and emotional cost, and places a significant financial burden 
to society at large (Ackery et al., 2004). Even though years of research have led to a better 
understanding in the pathophysiology of permanent neural injuries at the cellular level, 
much of the mechanism and processes of secondary injury at the molecular level remain to 
be elucidated. With modern molecular strategies and techniques, breakthroughs in the 
understanding of neuronal injury and neural regeneration provide new promises for 
reversal of spinal cord injury that once was thought to be permanent and irreversible 
(Carlson and Gorden, 2002).  
Spinal cord injury involves an initial mechanical or primary injury followed by a series of 
cellular and molecular secondary events that amplify the extent of the initial damage and 
results in the progressive destruction of spinal cord tissue. After acute contusion, the spinal 
cord undergoes a sequential progression of pathologic changes, including micro 
hemorrhage, cytotoxic edema, neuronal necrosis, axonal fragmentation, demyelination, 
further secondary cellular destruction and eventually cyst formation (Balentine, 1978; 
Balentine and Greene, 1984; Coutts and Keirstead, 2008). Damage to the spinal cord results 
in extensive proliferation of microglia and macrophages in and around the injury epicenter. 
This acute inflammatory response at the injury site is at least partly responsible for 
secondary spinal cord injury ( Popovich et al., 1997; Carlson et al., 1998; Taoka et al., 1998). 
The inflammatory cells (particularly macrophages/microglia) mediate tissue damage by 
producing a variety of cytotoxic factors including interleukins (Rice et al., 2007) and tumor 
necrosis factor-alpha (TNF-α) (Beattie et al., 2002). White matter breakdown begins at the 
grey-white matter junction with progressive edema (Dohrmann et al., 1972). Axoplasmic 
stasis and axonal swelling that contains multiple organelles, mitochondria, neurofilament, 
and smooth endoplasmic reticulum eventually undergo glandular dissolution and myelin 
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 disruption (Bresnahan et al., 1976; Balentine, 1978; Bresnahan, 1978; Balentine and Greene, 
1984). Within 4h of injury, neuronal and oligodendroglial cell loss is apparent in the lesion 
epicenter, and extends rostrally and caudally (Grossman et al., 2001). Within days after the 
injury polymorphonuclear cells and macrophages begin to infiltrate the injured region 
(Blight, 1985; Means and Anderson, 1983). And within one week, the central necrotic region 
begins to show cystic changes. By four weeks, chronic changes have occurred, and a cystic 
cavity remains with astrocytic gliosis and demyelination of the remaining axons (Wagner et 
al., 1971). Even years after initial trauma, neuronal and oligodendroglial apoptotic cell death 
processes continues to contribute to demyelination and Wallerian degeneration (Hagg and 
Oudega, 2006; Taoka and Okajima, 1998). The wave of post-traumatic tissue destruction, as 
initiated by secondary injury mechanisms, include disruption of spinal cord vasculature and 
ischemia, glutamatergic excitotoxicity, oxidative cell stress, lipid peroxidation and 
inflammation (Nashmi and Fehlings, 2001; Tator and Fehlings, 1991)—all of which alone or 
in concert can trigger apoptosis, contribute to the permanency of functional motor and 
sensory deficits (Hagg and Oudega, 2006; Taoka and Okajima, 1998). 
Apoptotic cell death has been observed to occur for weeks after injury at distance remote 
from the point of mechanical impact (Crowe et al., 1997; Emery et al., 1998; Springer et al., 
1999). Neurons and oligodendrocytes are especially vulnerable to the toxicity of the acute 
lesion microenvironment after SCI for several reasons (Choi, 1988). Neurons have a high 
rate of oxidative metabolism that makes them susceptible to injury by reactive oxygen 
species (ROS) following ischemia (Juurlink and Paterson, 1998). Compared to their 
supporting astroglial cells, neurons have lower levels of antioxidant levels (e.g., glutathione) 
and respond differently to molecular mechanisms involving the activation of Phase II 
enzymes, which are responsible for neutralization of damaging free radicals (Eftekharpour 
et al., 2000). Oligodendrocytes are also very susceptible to ROS due to their higher iron 
content and lower levels of glutathione and its related antioxidant enzymes, (Juurlink and 
Paterson, 1998). The oxidative stress by induction of ROS and pro-inflammatory cytokines 
initiates a cascade of oxidative events that lead to cell death due to a combination of necrosis 
and apoptosis (Crowe et al., 1997). Loss of oligodendroglia causes demyelination, impairs 
axonal function and survival. In the days to weeks after injury, disrupted neuronal axons 
and extracellular elements of the necrotic core at the site of injury are removed by recruited 
inflammatory cells and phagocytes (Dusart and Schwab, 1994), leaving in place fluid-filled 
cystic cavities at the site of injury (Greitz, 2006). 
2. Apoptosis after SCI 
Apoptosis is a genetically controlled cell death that is characterized by intact membrane 
integrity, cytoplasmic and nuclear condensation, loss of cellular volume, membrane bleb 
formation and nuclear disintegration (Yakovlev and Faden, 2001). The cell eventually 
fragments into apoptotic bodies, which are then engulfed and degraded by neighboring 
cells. During apoptosis, morphological changes are often accompanied by internucleosomal 
cleavage of genomic DNA (Wyllie et al., 1980). In the secondary injury process after SCI, 
apoptosis has been well documented. Emery et al., (1998) analyzed the spinal cords of 15 
patients who had died after traumatic SCI and described evidence of apoptotic cells at the 
edges of the lesion epicenter and in the adjacent white matter. Apoptotic mechanisms of cell 
death have been implicated in delayed Wallerian degeneration of white matter after spinal 
cord injury (Crowe et al., 1997). Oligodendrocytes, microglia, and neurons are susceptible to 
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apoptosis. After SCI, some cellular demise was directly related to post-traumatic necrosis, 
whereas others die due to apoptosis (Crowe et al., 1997; Emery et al., 1998; Shuman et al., 
1997; Springer et al., 1999; Keane et al., 2001; Warden et al., 2001; Beattie et al., 2002). Spinal 
cord trauma activates upregulation of caspases and calpain and the apoptotic machinery, 
leading to increased expression of death receptors and their ligands (Banik et al., 1997; 
Casha et al., 2001; Keane et al., 2001; Springer et al., 1999). However, there are conflicting 
reports as to the role of cell death in SCI— probably a reflection of the known dual capacity 
of TNF to be both pro- and anti-apoptotic. Fas/CD95, TNFR1 and TNFR2 have been mainly 
characterized in the immune system and are primarily involved in regulating inflammatory 
and apoptotic responses. However, these receptors and their ligands are also detectable in 
CNS tissue (both normal and traumatized), implicating their roles in neuronal maturation as 
well as in neurological trauma and disease. Apoptotic pathways triggered after SCI are 
depicted in Figure 1. 
 
 
Fig. 1. Apoptotic pathways triggered after SCI 
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Apoptosis of the cells takes place either rostral or caudal to the area of original damage. 
These are mainly either Fas-activated or TNF-α or JNK-activated pathways. In Fas-mediated 
pathway, Fas is activated by Fas ligand, whereby Fas-associated death domain (FADD) and 
caspase-8 are recruited to Fas to form the death-inducing signaling complex (DISC). 
Subsequently, caspase-8 can autoactivate and trigger cell death by cleavage of Bid and 
activation of effector caspases- 3 and -7. The activation and involvement of mitochondria in 
apoptosis appears to be the main pathway responsible for cell death. In tumor necrosis 
factor receptor 1 (TNFR1/TNFR2) signaling, early after trauma, increased levels of 
TNFR1/TNFR2 are activated where they associate with the adaptor protein TRADD, Fas-
associated death domain (FADD), TRAF2, TRAF1, and RIP. In later stages after injury, RIP 
and cIAP-1 appear to dissociate from the TNFR1 complex by an unknown mechanism and 
this complex signals death by activating caspase-8. In either case, activated caspase-3 
translocates to nucleus, and activates CAD resulting in cleavage of PARP leading to 
apoptotic cell death. In JNK mediated pathway, JNK gets activated after SCI, and 
translocated to nucleus where it activates c-Jun leading to apoptotic cell death. In 
mesenchymal stem cell treatment for apoptosis, mesenchymal stem cells are injected at the 
site of injury or rostral or caudal to the site of injury. 
2.1 Apoptosis involving FAS/CD95 and caspases 
Fas (CD95 or Apo-1) is a member of the TNFR superfamily and is one of six known death 
receptors. Fas exists as a 45-kDa, type 1 transmembrane protein with an elongated 
extracellular domain. This extracellular region contains three cysteine-rich domains (CRDs), 
which are typical of TNF receptors (Keane et al., 2006). This receptor contains a death 
domain and plays a central role in the physiological regulation of programmed cell death, 
and has been implicated in the pathogenesis of various malignancies and diseases of the 
immune system. The interaction of this receptor with its ligand generates the formation of a 
death-inducing signaling complex that includes Fas-associated death domain protein 
(FADD), caspase-8, and caspase-10. The autoproteolytic processing of the caspases in the 
complex triggers a downstream caspase cascade, and leads to apoptosis. The typical ligand 
for Fas is FasL (CD95L, Apo-1L, Cd178, TNFSF6), which is a 281–amino acid protein 
produced as a type 2 transmembrane protein and is highly restricted to immune cells and 
cells of the CNS. In the nervous system, Fas/CD95 activation can lead to cell death 
involving neurons and glial cells (D'Souza et al., 1995; Raoul et al., 2002). Activation of 
Fas/CD95 can also lead to enhanced axonal growth (Desbarats et al., 2003). Fas and FasL are 
expressed in the normal CNS, and are upregulated in inflamed and degenerated brains 
(Choi and Benveniste, 2004). Fas and FasL levels have been found to be elevated after SCI 
(Casha et al., 2001; Dasari et al., 2008; Demjen et al., 2004; Li et al., 2000a). Yoshino et al., 
(Yoshino et al., 2004) investigated Fas/CD95-mediated apoptosis after SCI using Fas-
deficient mutant mice. Mice lacking Fas/FasL showed improved functional recovery, 
decreased lesion size, and fewer apoptotic cells in the injured cord than control littermates. 
It appears that Fas-FasL induce apoptosis via both intrinsic and extrinsic pathways. The 
extrinsic pathway involves Fas-FasL mediated activation of caspase-8, which then directly 
activates caspase-3 (Salvesen and Dixit, 1999; Stennicke et al., 1998). There was evidence to 
support the regulation of intrinsic mitochondrial apoptotic pathways by the Bcl-2 family 
proteins, which consists of both pro-apoptotic (Bid and Bax) and anti-apoptotic (Bcl-2 and 
Bcl-xL) members (Kim et al., 2000). In addition, the intrinsic pathway can be initiated by the 
www.intechopen.com
 Mesenchymal Stem Cell Therapy for Apoptosis After Spinal Cord Injury 
 
369 
extrinsic pathway, thereby amplifying the apoptotic process. In this scenario, Caspase-8 
cleaves Bid into truncated tBid, which translocates from the cytosol into the mitochondria, 
releasing cytochrome c and activating caspase-3 and -9 (Kuwana et al., 1998; Li et al., 1998; 
Scaffidi et al., 1998; Stennicke et al., 1998; Verhagen et al., 2000). Also, a mitochondrial 
apoptotic protein, Apoptosis-inducing factor (AIF), was found capable of inducing neuronal 
apoptosis when translocated from mitochondria to the nucleus via a caspase-dependent 
pathway (Tsujimoto, 2003; Tsujimoto and Shimizu, 2000; Yu et al., 2006; Yu et al., 2009).  
Strategies to inhibit Fas-FasL cascade may provide effective neuroprotective approaches for 
mollifying apoptosis after SCI. In one experiment, neutralization of FasL, but not TNF, 
significantly decreased apoptotic cell death after SCI (Demjen et al., 2004). Mice pretreated 
with FasL-specific antibodies were capable of initiating active hind-limb movements several 
weeks after injury with upregulation of growth-associated protein Gap-43 and more 
abundance in regenerating fibers. Thus, neutralization of FasL appears to diminish 
apoptotic cell death and promote axonal regeneration and functional improvement in 
injured adult animals (Demjen et al., 2004). Other experiments have demonstrated that 
blocking Fas activation using soluble Fas receptors for competitive inhibition or 
neutralization using anti-FasL antibody diminished brain injury volume and improved 
outcome in a stroke model of mouse (Gao et al., 2005). The neuroprotective effect of anti-
FasL in animal models of SCI, stroke and multiple sclerosis has stimulated considerable 
interest in elucidation of the role of the Fas/CD95/FasL system in CNS neurons (Demjen et 
al., 2004; Martin-Villalba et al., 1999; Waldner et al., 1997). However, a true understanding of 
how FasL antibodies reduce cell death and enhance recovery requires more detailed 
knowledge. It is not clear if CNS cells exhibit differences in the efficiency of Fas/CD95 
signaling and thus can be categorized as type I or type II cells (Keane et al., 2006). The 
cellular source and target of the ligand in damaged CNS tissue need to be identified, and 
strategies need to be developed for effective delivering antibodies to the lesion. Recent 
experimental evidence has provided some knowledge about receptor submembrane 
localization and the formation of alternative signaling complexes that can alter the fate of 
cells in vitro, but whether these principles hold true in vivo remained to be explored. Thus, 
activation of these signaling pathways might result in promising therapeutic targets for the 
acute treatment of neurological trauma and disease. 
In addition to FasL/CD95 involvement in apoptosis, caspases are also known to be 
powerful mediators of programmed cell-death in CNS injury and disease processes. All 
caspases are translated initially as inactive zymogens that are then activated after specific 
cleavage. They have the following structural features in common: an N-terminal pro-
domain of variable length (22 to >200 amino acids), a large subunit (~ 17-20 kDa), a short 
inter-subunit region (~10 amino acids), and a small subunit (~10—12 kDa). The C-terminal 
portion of the large subunit contains the catalytic cysteine residue. Flanking this are other 
conserved residues that, together, form the semiconserved pentapeptide sequence QACXG 
at the active site (Alnemri et al., 1996; Thornberry and Lazebnik, 1998). Pro-caspases are 
processed by limited proteolysis into their active form, which consists of a large and small 
subunit dimer. In vivo, however, caspases are more conformationally stable as tetramers 
consisting of two large/small subunit dimers (Eldadah and Faden, 2000). Once activated by 
specific cleavage to active forms, caspases can activate other procaspases via extrinsic 
pathway directly or intrinsic pathway by mitochondrial-dependent mechanisms, thereby 
amplifying the programmed cell death process (Li et al., 1998; Scaffidi et al., 1998; Slee et al., 
1999; Yakovlev and Faden, 2001; Yu et al., 2009). Based on their putative functions and 
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sequence homologies, caspases are often categorized into three groups: apoptotic initiators 
(caspase-2, 8, -9 and -10), apoptotic executioners (caspase- 3, -6, and -7), and inflammatory 
mediators (caspase -1, -4,-5, -11, -12, and -13) (Alenzi et al., 2010; Thornberry and Lazebnik, 
1998). The apoptotic initiators, act at upstream positions within apoptotic pathways; that is, 
the cell surface and mitochondria. They have in common long N-terminal pro-domains that 
contain six anti-parallel α-helices with complementary binding capability. Caspases-8 and -
10 have two such domains at their N-termini known as death effector domains (DEDs). 
Caspases-2 and -9 have only one of these domains, which, in the case of these members, are 
known as caspase recruitment domains (CARDs). These sequences play an important role in 
localization and activation of specific procaspases. The apoptotic executioners mediate some 
of the morphological and biochemical manifestations of apoptosis: plasma membrane 
blebbing, nuclear membrane dissolution, chromatin condensation and margination, and 
DNA fragmentation. Executioner caspases have short N-terminal pro-domains whose 
function remains unclear (Eldadah and Faden, 2000). The third group of caspases is 
inflammatory mediating proteases that are poor substrates for other caspases and their 
activation pathways are not well understood. 
Numerous studies have demonstrated the presence of multiple caspases and apoptosis 
following SCI (Beattie et al., 2000; Citron et al., 2000; Crowe et al., 1997; Eldadah and Faden, 
2000; Keane et al., 2001; Liu et al., 1997; Lou et al., 1998; Springer et al., 1999; Yong et al., 
1998). Emery et al., (1998) have reported substantial labeling of active caspase-3 around the 
injury site in histological study of injured spinal cords from 15 patients who died after 
traumatic SCI. The involvement of caspase-3 as a major effector in injury-induced neuronal 
apoptosis was established by using specific caspase inhibitors in various models of ischemic 
or traumatic injury (Clark et al., 2000; Gillardon et al., 1997; Gottron et al., 1997; Namura et 
al., 1998; Yakovlev et al., 1997). Caspase-3 can be activated by caspases-8, -9, -11, and -12 
(Kang et al., 2000; Wang et al., 1998). Caspases-11 and -12 in turn can be activated by 
Calpain and Cathepsin B (Nakagawa and Yuan, 2000; Schotte et al., 1998; Yamashima, 2000). 
Apoptosis therefore plays an important role in the secondary injury processes following 
traumatic injury to the CNS (Crowe et al., 1997; Keane et al., 2001; Li et al., 1996; Lu et al., 
2000). The permanent neurological deficits after spinal cord injury may be due in part to 
widespread apoptosis in regions distant from and relatively unaffected by the initial injury 
(Crowe et al., 1997). Caspases were one of the viable therapeutic targets for modulating 
apoptosis and remain the viable approach to blocking apoptotic cell death (Nicholson, 2000). 
A number of caspase inhibitors such as z-VAD fmk (N-benzyloxycarbonyl-Val-Ala-Asp-
fluoromethylketones) have been developed to avert apoptotic chain events. X-linked 
inhibitor of apoptosis proteins (XIAP) has been identified as one of the mammalian 
homologues in the IAP family, and has been demonstrated to inhibit cell death (Ekert et al., 
1999). During apoptosis, XIAP is cleaved to generate fragments with distinct specificity for 
caspases (Deveraux et al., 1999). However, caspase inhibition has yet to be used in clinical 
setting despite demonstrated efficacy in treatment of various CNS insults of in vivo models 
(Braun et al., 1999; Hara et al., 1997; Li et al., 2000b; Yakovlev et al., 1997). Several SCI 
experiments using caspase inhibitors have been reported (Li et al., 2000a; Lou et al., 1998; 
Springer et al., 1999) to mitigate injury-induced programmed cell death. 
2.2 Apoptosis involving TNF-α mediated pathway 
Tumor necrosis factor (TNF)-α, also known as cachexin or cachectin, is a pro-inflammatory, 
pro-apoptotic cytokine that elicits diverse biological actions, including the induction of 
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apoptosis (Tracey, 2011). TNF-α is a trimeric protein primarily produced by the brain 
resident immune cells such as monocytes and macrophages (the microglia cells) in response 
to various stimuli (Leung and Cahill, 2010). TNF-α is initially synthesized as a 26-kD cell 
surface-associated molecule (membrane-bound form) which is then cleaved into a soluble 
17-kD form by TNF-converting enzyme (Grewal, 2009). The known roles of TNF-α have 
extended from the immune system to neuro-inflammatory domain in the nervous system 
(Leung and Cahill, 2010). TNF-α induces central sensitization and hyperalgesia by 
increasing excitatory synaptic transmission (Kawasaki et al., 2008). TNF-α initiates the 
activation of several cytokines and growth factors, as well as the recruitment of some 
immune cells. Cytokines exist in ‘cascades’ and interrupting one cytokine can disrupt the 
cascade. For example, blocking TNF-α reduces the activity of IL-6 and IL-1b (Fong et al., 
1989); whereas blocking IL-1b reduces IL-6 (Goldbach-Mansky et al., 2006); and blocking IL-
12 and IL-23 reduces IFN-γ. It is this ‘master role’ in cytokine function that makes TNF-α an 
attractive target in SCI and other disorders involving inflammation and apoptosis. TNF-α 
interacts with two distinct receptors – TNFR-55 (TNFR1, p55, CD120a) and TNFR-75 
(TNFR2, p75, CD120b). TNF-α can either bind directly to TNFR1 and TNFR2 through cell-
to-cell contact or undergo cleavage and binds in its soluble form (Vandenabeele et al., 1995). 
All nucleated cells express TNF receptors. TNFR1 is expressed constitutively on most cell 
types, whereas expression of TNFR2 can be induced by TNF-α, interleukin (IL)-1, and 
interferon (IFN)-α in rat primary astrocytes (Choi et al., 2005). In addition, TNFR2 
expression is restricted to hematopoetic cells and can discriminate between murine and 
human forms of TNF-α (Tartaglia et al., 1991). The receptors also differ significantly in their 
binding affinity for homotrimeric TNF-α. Although both receptors can be considered high-
affinity, the on–off kinetics of the two differs dramatically. Binding of homotrimeric TNF-α 
to TNFR1 seems to be essentially irreversible, whereas binding to TNFR2 is associated with 
rapid on–off kinetics (Choi et al., 2005). 
Evidence showed that proinflammatory and proapoptotic cytokines, including TNF-α, IL-1γ, 
and FasL regulate cellular events and contributes to neuronal damage and functional 
impairment associated with SCI (Harrington et al., 2005; Lee et al., 2000; Martin-Villalba et 
al., 1999; Streit et al., 1998). TNF-α levels become elevated in human spinal cord after SCI, 
reaching a peak within 1h after the initial trauma (Dinomais et al., 2009). The expression of 
TNF-α is upregulated rapidly at the lesion site after SCI (Hayashi et al., 2000; Streit et al., 
1998; Wang et al., 1996; Wang et al., 2002; Yan et al., 2001). TNF-α can induce apoptosis of 
oligodendrocytes and neuronal cell line in vitro (D'Souza et al., 1995; Sipe et al., 1996). Rapid 
accumulation of TNF-α may act as an external signal initiating apoptosis after SCI in 
neurons and glial cells (Lee et al., 2000; Shuman et al., 1997). Neutralization of TNF-α 
reduced the number of apoptotic cells after SCI (Lee et al., 2000). Apoptosis induced by 
TNF-α after SCI could be mediated in part by nitric oxide via upregulation of inducible 
nitric oxide synthase (iNOS) (Yune et al., 2003). Although, few studies indicate a 
neuroprotective role of TNF-α and NOS expression in SCI, several investigators support a 
neurodestructive role of these agents in spinal cord pathology (Bethea et al., 1999; Bethea 
and Dietrich, 2002; Dolga et al., 2008; Gonz'alez Deniselle et al., 2001; Sharma et al., 1995; 
Sharma, 2007; Sharma, 2008; Sharma, 2010; Stalberg et al., 1998). 
Apoptosis of oligodendrocytes in vivo was shown to be induced by the overexpression of 
TNFR1 (Akassoglou et al., 1998). Following SCI, TNFR1 and TNFR2 expression is elevated 
in the injured spinal cord and localized on neurons, astrocytes and oligodendrocytes (Yan et 
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al., 2003). TNFR1 and TNFR2 are elevated as soon as 15 min after traumatic SCI in adult rats, 
reaches the peak at 4h for TNFR2 and 8h for TNFR1, and declines markedly after 1 day and 
3 days (Yan et al., 2003). TNFR1 immunoreactivity was demonstrated on cells and afferent 
fibers of dorsal root and dorsal root ganglia, dorsal root entry zone and within lamina I and 
II of dorsal horn, whereas TNFR2 expression was absent in these regions (Holmes et al., 
2004). These two receptors might work individually or synergistically to mediate the 
biological activity of TNF-α. It has been suggested that TNF receptors are involved in anti-
apoptotic activities through the TNFR1-nuclear factor kappa B (NFκB) signal transduction 
pathway, which activates a recently identified endogenous caspase inhibitory system that is 
mediated by cellular inhibitor of apoptosis protein 2 (c-IAP2) (Kim et al., 2001). After TNF 
binding to TNFR1, a TNFR1 receptor–associated complex (complex-I) forms and contains 
TRADD, RIP1, TRAF1, TRAF2, and cIAP-1. Complex-I transduce signals that lead to NF-κB 
activation through recruitment of the IκB kinase ‘signalsome’ high-molecular-weight 
complex (Poyet et al., 2000; Zhang et al., 2000). TNFR1-/- mice had greater numbers of 
apoptotic cells, larger contusion size, and worse functional recovery after SCI. TNFR2-/- 
mice had similar, although not as pronounced, consequences as the TNFR1-/- mice. 
However, when new protein synthesis is inhibited prior to TNF stimulation, TNFR1 can 
initiate apoptosis by activation of apical caspases (Varfolomeev and Ashkenazi, 2004). 
TNFR1-mediated apoptosis signaling is induced in which TRADD and RIP1 associate with 
FADD and caspase-8 to form a cytoplasmic complex (complex-II) that dissociates from 
TNFR1. When complex-I triggers sufficient NF-κB signaling, anti-apoptotic gene expression 
is induced and the activation of initiator caspases in complex-II is inhibited. If NFκB 
signaling is deficient, complex-II transduces an apoptotic signal. Thus, early activation of 
NFκB by complex-I serves as a checkpoint to regulate whether complex-II induces apoptosis 
at a later time point after TNF binding. 
2.3 Apoptosis involving JNK mediated pathway 
The mitogen-activated protein kinases (MAPKs) are a family of evolutionally conserved 
molecules that play a critical role in cell signaling and gene expression. MAPK family 
includes three major members: c-Jun N-terminal kinase (JNK), p38 and extracellular signal 
regulated kinase (ERK), representing three different signaling cascades. The JNK pathway is 
considered as a key mediator of stress-induced apoptosis (Davis, 2000). Examples include 
neuronal apoptosis induced by NGF withdrawal (Eilers et al., 1998; Park et al., 1996; Xia et 
al., 1995), excitotoxic stress (Yang et al., 1997b) and UV radiation (Tournier et al., 2000; 
Tournier et al., 2001), thymocyte apoptosis induced by anti-CD3 antibody (Rincon et al., 
1998; Sabapathy et al., 1999) and endothelial cell apoptosis caused by diabetes-associated 
hyperglycemia (Ho et al., 2000). JNK pathway activation may also contribute to neuronal 
death in neurodegenerative diseases including Alzheimer’s, Parkinson’s, Huntington’s 
Diseases and stroke (Gao et al., 2005; Okuno et al., 2004; Yang et al., 1997b). However, the 
mechanism by which JNK activation triggers apoptotic processes remains to be fully 
elucidated. Substrates of JNK, including the Bcl-2 family proteins, regulate cytochrome c 
release which is an important event in apoptosis secondary to mitochondrial dysfunction. 
After SCI, JNK3 activity itself is induced by the injury, regulating cytochrome C release by 
phosphorylating Mcl-1, and thereby facilitating the degradation of Mcl-1, which is necessary 
for induction of apoptosis of oligodendrocytes (Li et al., 2007). Although JNK3 is also 
activated in neurons after SCI, it did not induce neuronal apoptosis. A potential role for 
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JNK3 in neurons is regulation of autophagic death instead of apoptotic death as observed in 
oligodendrocytes (Li et al., 2007). Several studies demonstrated that the anti-apoptotic 
proteins Bcl-2, Bcl-xL and Mcl-1 are phosphorylated by JNK in vitro and in vivo (Inoshita et 
al., 2002; Maundrell et al., 1997; Yamamoto et al., 1999), there by suppressing the anti-
apoptotic activity of these proteins. Another possibility is that JNK phosphorylates the 
transcription factor c-Jun which might in turn mediate the induction of proteins regulating 
cytochrome c release in apoptosis (Behrens et al., 1999). Indeed, JNK has been found to 
regulate some pro-apoptotic BH3-only proteins via transcription-dependent mechanisms 
(Tournier et al., 2000). Two genes in this subfamily, DP5 and Bim, have AP-1 binding sites 
on their promoters, and transcription appears to be regulated by JNK activity (Davis, 2000; 
Harris and Johnson, Jr., 2001; Putcha et al., 2001; Putcha et al., 2003; Whitfield et al., 2001; 
Yang et al., 1997a; Yin et al., 2005).  
Substantial increases in p-JNK expression were noticed after SCI (Esposito et al., 2009; Yin et 
al., 2005). Activated form of JNK was expressed in the apoptotic cells that were stained by 
oligodendrocyte antibodies 1–3 days after SCI (Nakahara et al., 1999) and both p-JNK and 
DP5 colocalization were found in neurons and oligodendrocytes undergoing apoptosis after 
SCI (Yin et al., 2005). Similarly, the transcription factor, c-Jun (which is an exclusive 
substrate of JNK), was also phosphorylated shortly after traumatic injury. Furthermore, DP5 
is also induced after SCI in a JNK-dependent manner. Suppression of JNK activity by 
SP600125, a JNK inhibitor, or jnk1 knockdown by an antisense oligodeoxynucleotide (ODN) 
attenuated SCI-induced DP5 upregulation and caspase-3 activation. Following traumatic 
SCI, JNK activation contributes to activation of caspase 3, and apoptosis of glia and neurons 
(Yin et al., 2005). Based on these discoveries, it appears that JNK/c-Jun/DP5/Caspase 3 
signaling pathway could represent a potential target for therapeutic interventions in SCI.  
3. Stem cell therapy for apoptosis after SCI 
During the first few days after injury, there are many microenvironmental features that are 
detrimental to the survival and integration of transplanted stem cells (Hausmann, 2003). The 
pathophysiologic processes initiated after acute spinal cord injury are extremely complex, 
and our limited understanding is reflected in the utilization of i.v. steroid trauma protocol as 
the only currently available neuroprotective strategy. The limited success of pharmacologic 
treatment has shifted the focus of medical research away from these traditional treatments 
to other more promising areas such as cell-based therapy, particularly, the application of 
stem cell biology (Hipp and Atala, 2004; Stanworth and Newland, 2001). Thus, various 
cellular transplantation strategies have been utilized in different models of SCI 
(Eftekharpour et al., 2008). The adult spinal cord harbors endogenous stem/progenitor cells, 
collectively referred to as NPCs, which might be responsible for normal cell turnover. 
However, the proliferative activity of endogenous NPCs is too limited to support significant 
self repair after injury. As such, stem cell transplantation has become a very attractive and 
viable treatment option for not only CNS injury but also other neurodegenerative disease 
processes such as Parkinson disease, MS, stroke and ALS (Malgieri et al., 2010). The 
rationale for cell replacement approach for the treatment of SCI are (1) regeneration, which 
seeks to replace lost or damaged neurons and induce axonal regeneration or modulate 
plasticity; and (2) repair, which seeks to replace supportive cells such as oligodendrocytes in 
order to prevent progressive myelin loss and induce remyelination (Totoiu and Keirstead, 
2005). Additionally, stem cell transplantation may promote protection of endogenous cells  
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from further cell loss by attenuation of secondary injury process. Non-embryonic sources of 
adult stem cells, free from many of the ethical and legal concerns associated with embryonic 
stem cell research, may offer great promise for the advancement of medicine (Moore et al., 
2006). At present, the only non-embryonic stem cells easily available in large numbers are 
found in the bone marrow, adipose tissue and human umbilical cord blood. These 
multipotent adult stem cells are ideal vehicles for gene therapy, and genetic engineering for 
therapeutic treatment of various genetic disorders (Pessina and Gribaldo, 2006). Recent 
studies have shown that transplanted adult stem cells, including mesenchymal stem cells, 
human umbilical cord blood stem cells into injured spinal cord promote endogenous myelin 
repair and modulate immune response, stirring the hope of applying their efficacy to other 
demyelinating diseases such as MS and stroke.  
3.1 Mesenchymal stem cells 
Mesenchymal stem cells (MSC) are stromal cells from the bone marrow (BM) and appear as 
spindle-shaped cells in culture (Friedenstein et al., 1974). Human mesenchymal stem cells 
are multipotent cells that are present in adult marrow, can replicate as undifferentiated cells 
and have the potential to differentiate to lineages of mesenchymal tissues, including bone, 
cartilage, fat, tendon, muscle, and marrow stroma (Pittenger et al., 1999). Even though not 
immortal, they have the ability to expand many folds in culture while retaining their growth 
and multilineage potential. MSC are identified by the expression of surface markers 
including CD105 (SH2) and CD73, and are negative for hematopoietic markers such as 
CD34, CD45 and CD14. MSC attracted interest for their ability to migrate to the injured site 
and differentiate into multiple cellular phenotypes in vivo (Uccelli et al., 2011). The 
heterogenity of MSC, and their expression of a large number of regulatory proteins, may 
explain their wide therapeutic features and capacity to respond differently to injuries 
depending on the microenvironment, despite their low engraftment in vivo (Phinney and 
Prockop, 2007). MSC produce cytokines and a variety of soluble factors regulating several 
biological activities as demonstrated by their transcriptome analysis (Phinney et al., 2006). 
They play a major role in the maintenance of local homeostasis via their supporting activity 
in the survival of non-proliferating hematopoietic stem cells (HSC) niche in the bone 
marrow (Mendez-Ferrer et al., 2010). These mesenchymal stem cells are derived from the 
embryonic mesodermal layer and retain the cardinal abilities of stemcellness for self-
renewal and multipotentiality to differentiate into various tissue cell types. 
MSCs are attractive candidates for cellular therapies because they are easy to isolate, have a 
broad differentiation potential, and proliferate in vitro (Barry, 2003). Bone Marrow and 
umbilical cord blood are rich sources of these cells, but MSC have also been isolated from fat 
(Gronthos et al., 2001), skeletal muscle (Jankowski et al., 2002), human deciduous teeth 
(Miura et al., 2003), and trabecular bone (Noth et al., 2002). In addition, recent data 
demonstrated that MSC can give rise to cells of non-mesodermal origin such as hepatocytes, 
epithelial and neural cells (Chagraoui et al., 2003; Ma et al., 2006; Spees et al., 2003; 
Woodbury et al., 2000). The choice of the tissue source is governed by availability, as well as 
by the degree of characterization of the cells and the consistency of the preparations. MSCs 
from bone marrow and umbilical cord blood have been reasonably well defined in terms of 
surface markers and differentiation pathways. These donor sites provide a readily available 
autologous source for cell transplantation, alleviating the need for long-term 
immunosuppression. Mesenchymal stem cells have been used in experimental models of 
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SCI and in preliminary clinical trials for SCI (Himes et al., 2006; Sykova et al., 2006) with 
apparent improvement of behavioral outcome. Stem cells are likely to be therapeutically 
valuable both in providing permissive substrates for axonal regeneration and as ‘cellular 
minipumps’ delivering trophic factors that could enhance white matter sparing and/or 
axonal regeneration (Enzmann et al., 2006). The functional benefits of MSC transplantation 
in CNS injuries can be explained by their ability to provide the host tissue with growth 
factors or modulate the host immune system (Garbuzova-Davis et al., 2006). One of the 
major goals for the therapeutic use of stem cells is to prevent apoptosis or to replace lost 
cells, particularly oligodendrocytes, in order to facilitate the remyelination of spared axons. 
Details showing application of unengineered mesenchymal stem cells from various sources 
and their applications after SCI are provided in Table 1. 
3.1.1 Bone marrow derived mesenchymal stem cells 
Human MSCs are isolated from a bone marrow (BM) aspirate, which is often harvested from 
the superior iliac crest of the pelvis. They represent a very minor fraction of the total 
nucleated cell population in marrow, but can be plated and enriched using standard cell 
culture techniques. Frequently, the marrow sample is subjected to fractionation on a density 
gradient solution, such as Percoll, after which the cells are plated. Primary cultures are 
usually maintained for 12–16 days, and are then detached by trypsinization and 
subcultured. Morphologically, the cells resemble adherent fibroblasts (Barry, 2003). Under 
physiological settings bone marrow derived MSC (BMSC) main function is to regulate 
hematopoiesis. However, when these cells are grown away from their natural environment, 
they can be readily and effectively propagated and manipulated genetically into cells of the 
mesodermal lineage but also, under certain experimental circumstances, into cells of the 
neuronal and glial lineage (Clark and Keating, 1995). The advantages of using bone marrow 
as a source for stem cells are numerous: they are relatively easy to isolate, the cells grow and 
expand well in tissue culture. BMSC may be used in autologous transplantation protocols, 
and these have already received FDA approval for treatment of hematopoietic diseases 
(Sykova et al., 2006). BMSC therapeutic value relies on their significant anti-proliferative, 
anti-inflammatory and anti-apoptotic features. These properties have been demonstrated in 
the treatment of experimental autoimmune encephalomyelitis (EAE), an animal model of 
multiple sclerosis where inhibition of the autoimmune response resulted in a significant 
neuroprotection.  
BMSC transplantation results in neuroprotection and increased endogenous neuronal 
survival in experimental brain ischemia, traumatic brain and spinal cord injury models 
(Uccelli et al., 2011). There is increasing evidence that MSCs possess immunosuppressive 
features (Bartholomew et al., 2002; Corcione et al., 2006; Di Nicola et al., 2002; Jiang et al., 
2005). These immunosuppressive properties in combination with their restorative functions 
reduce the acute inflammatory response to SCI, minimize cavity formation, as well as 
diminish astrocyte and microglia/macrophage reactivity (Abrams et al., 2009; Himes et al., 
2006; Neuhuber et al., 2005). BMSC administered 1- week post-SCI had better rates of 
survival since the microenvironment has become less hostile by then. MSC transplantation 
in an experimental SCI model has been shown to enhance tissue protection and cellular 
preservation via reduction in injury-induced sensitivity to mechanical trauma (Abrams et al., 
2009). These studies indicated that transplanted MSC attenuates acute inflammation and 
promote functional recovery following SCI (Hofstetter et al., 2002). Clinically, Park et al. (2005) 
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References Source of 
Mesenchymal 
stem cells  
Experimental 
Animals 
Route/site of 
administration 
Treatment 
timing 
Treatment outcome 
Cízková  
et al., 2006 
Human bone 
marrow  
Rats Into right femoral 
vein 
7 days after 
thoracic SCI 
Remyelination of spared 
white matter tracts, 
enhancing axonal growth 
and functional recovery 
Dasari  
et al., 2007a 
Rat bone 
marrow  
Rats Injury epicenter 7 days after 
thoracic SCI 
Downregulation of caspase 
mediated apoptosis, 
functional recovery of rats 
Dasari  
et al., 2008 
Human 
umbilical cord 
blood 
Rats Injury epicenter 7 days after 
thoracic SCI 
Downregulation of Fas 
mediated apoptosis, 
functional recovery of rats 
Dasari  
et al., 2009 
Human 
umbilical cord 
blood 
Rats Injury epicenter 7 days after 
thoracic SCI 
Downregulation of TNF-α 
mediated neuronal apoptosis  
Deng  
et al., 2006 
Rhesus monkey 
bone marrow 
Rhesus 
monkey 
Injury epicenter 7 days after 
thoracic SCI 
de novo neurogenesis and 
functional recovery 
Gu  
et al., 2010 
Rat bone 
marrow  
Rats 1mm rostral and 
caudal from 
injury epicenter 
7 days after 
thoracic SCI 
Reduction in lesion volume; 
axonal regrowth of injured 
spinal cord. 
Hu  
et al., 2010 
Human 
umbilical cord 
blood 
Rats 2mm rostral and 
caudal from 
injury epicenter 
24h after thoracic 
SCI 
Increased length of 
neurofilament positive fibers 
and increased numbers of 
growth cone-like structures 
around the lesion site, 
functional recovery 
Lee  
et al., 2007 
Human bone 
marrow  
Rats Injury epicenter 7 days after 
thoracic SCI 
Functional recovery 
Lim  
et al., 2007 
Umbilical cord 
blood of canine 
fetuses 
Dogs Injury epicenter 7 days after 
balloon 
compression at 
the first lumbar 
vertebra. 
Significant improvement in 
the nerve conduction 
velocity based on the 
somatosensory evoked 
potentials. Functional 
recovery. 
Osaka  
et al., 2010 
Rat bone 
marrow  
Rats Intravenous 
(through the 
femoral vein) 
6h, 1d, 3d, 10d, 
14d, 21d, 28d 
after thoracic SCI
Cavitation in the contused 
spinal cords was less; 
functional recovery 
Parr  
et al., 2008 
Rat bone 
marrow  
Rats Injury epicenter 9 days after clip 
compression 
injury at the 
thoracic region 
Potential axonal guidance 
through guiding strands of 
matrix generated by the bone 
marrow stromal cells 
Satake  
et al., 2004 
Rat bone 
marrow  
Rats Stem cells injected 
into the 
subarachnoid 
space 
3, 5, 7 days after 
thoracic SCI 
MSCs differentiated into 
Nestin-positive, immature 
neurons or glial cells 
Yang  
et al., 2008 
Wharton's jelly 
of the human 
umbilical cord 
Rats 2mm rostral and 
caudal to injury 
epicenter 
After complete 
transection at the 
thoracic region. 
Functional recovery, 
regenerated axons in the 
corticospinal tract and 
neurofilament-positive fibers 
around the lesion site. 
Zeng  
et al., 2011 
Rat bone 
marrow derived 
mesenchymal 
stem cells grown 
on 3D gelatin 
sponge (GS) 
scaffolds 
Rats Injury epicenter 7 days after 
thoracic SCI 
Attenuating inflammation, 
promoting angiogenesis and 
reducing cavity formation. 
Table 1. Table showing different authors using mesenchymal stem cells for treatment after SCI 
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evaluated the therapeutic efficacy of combining autologous BMSC transplantation, 
administered directly into the spinal cord lesion site, with granulocyte macrophage- colony 
stimulating factor (GM-CSF), given subcutaneously, in six patients with complete SCI. At 
the 6-month and 18-month follow-up periods, four of the six patients showed neurological 
improvements by two ASIA grade (from ASIA A to ASIA C), while another improved from 
ASIA A to ASIA B. Moreover, BMSC transplantation together with GM-CSF was not 
associated with increased morbidity or mortality. In another clinical trial, safety of 
autologous bone marrow cell implantation was tested in 20 patients (Sykova et al., 2006). 
Motor evoked potential, somatosensory evoked potential, magnetic resonance imaging, and 
ASIA scores were measured in patient follow-up. This study demonstrated that BMSC 
transplantation is a relatively safe procedure and BMSC-mediated repair can lead to modest 
improvements in some injured patients. Thus, it is anticipated that a Phase II clinical trial 
designed to test the efficacy will be initiated in the near future. In another study using 
human mesenchymal stem cells (hMSCs) derived from adult bone marrow, the transplanted 
cells were found to infiltrate mainly into the ventrolateral white matter tracts, spreading to 
adjacent segments rostro-caudal to the injury epicenter, and facilitate recovery from SCI by 
remyelinating spared white matter tracts and/or by enhancing axonal growth (Cizkova et 
al., 2006). In our laboratory, we used mesenchymal stem cells from rat bone marrow to 
evaluate the therapeutic potential after SCI (Dasari et al., 2007a). Immunohistochemistry 
confirmed a large number of apoptotic neurons and oligodendrocytes in caudal segments 2 
mm away from the lesion site. Expression of caspase-3 on both neurons and 
oligodendrocytes after SCI was significantly downregulated by BMSC. Treatment with 
BMSC had a positive effect on behavioral outcome and better structural integrity 
preservation as seen on histopathological analysis. BMSC secrete protective factors that 
prevent neuronal apoptosis through stimulation of endogenous survival signaling 
pathways, namely the PI3-K/Akt and the MAPK/Erk1, 2-cascade (Isele et al., 2007). The 
potential of bone marrow cell transplantation as a method of repair in the injured CNS may 
serve a number of different purposes that span various therapeutic targets. Animal studies 
have demonstrated that transplanted MSCs mollify the inflammatory response in the acute 
setting and reduce the inhibitory effects of scar tissue in the subacute/chronic setting to 
provide a permissive environment for axonal extension. In addition, grafted cells may 
provide a source of growth factors to enhance axonal elongation across spinal cord lesions 
(Wright et al., 2011). Moreover, SCI initiates an innate immune response that participates 
not only in secondary pathogenesis but also in wound healing (Trivedi et al., 2006). Even 
though the present data are promising, further research is needed to establish whether bone 
marrow cell treatments can serve as a safe and efficacious autologous source for the 
treatment of the injured SCI (Wright et al., 2011). Downregulation of TNF-α expression in 
macrophages/microglia was observed at an early stage after SCI in rats transplanted with a 
gelatin sponge scaffold impregnated with rat bone marrow-derived mesenchymal stem cells 
at the site of injury (Zeng et al., 2011). 
3.1.2 Human umbilical cord blood derived mesenchymal stem cells 
Human umbilical cord blood collected from umbilical vein following birth is a valuable 
source of mesenchymal stem cells (hUCB or hUCBSC) and has been used as an alternative 
source of allogenic donor cells to treat a variety of hematologic, immunologic and oncologic 
disorders (Broxmeyer et al., 1989; Gluckman et al., 1997; Han et al., 2003; Kim et al., 2002). 
www.intechopen.com
 Advanced Understanding of Neurodegenerative Diseases 
 
378 
Human umbilical cord blood contains a heterogeneous population of cells enriched in 
hematopoietic stem cells and display a high proliferative capacity (Mayani and Lansdorp, 
1998). These mesenchymal multipotent progenitor cells possess the capability of 
differentiating into diverse functional progenitors, including hematopoietic cell lineages, 
dendritic cells, cardiomyocytes, mesenchymal stem cell (MSC) progenitors, neural stem cell 
(NSC) progenitors, keratinocytes, hepatocytes, pancreatic β-cells, and endothelial cells in 
specific culture conditions in vitro and in vivo (Brunstein et al., 2007; Hemmoranta et al., 
2006; Mimeault and Batra, 2006; Weiss and Troyer, 2006). Complex interactions between 
adult stem cells, host cells and the specialized microenvironment may influence their 
behavior (Arai and Suda, 2007; Barrilleaux et al., 2006; Bryder et al., 2006; Moore et al., 2006; 
Wilson and Stice, 2006). More specifically, the reciprocal interactions of adult stem cells with 
neighboring cells via the formation of adherens junctions and the secretion of diverse soluble 
factors might contribute to their restricted mobility and the adoption of a quiescent or 
activated state within niches (Mimeault and Batra, 2006). There are many advantages of 
human umbilical cord blood as a source of MSC as compared to bone marrow or adipose 
tissue. First, the collection of cord blood is easy and painless. The cord blood can be stored 
for later use. Second, hUCBSC are more primitive than MSCs isolated from other tissue 
sources (Can and Karahuseyinoglu, 2007; Lu et al., 2006; Sarugaser et al., 2005; Wu et al., 
2007). Third, hUCBSC have a higher proliferative capacity and a faster population doubling 
time that remains unaltered after 30 passages. In contrast, BMSC showed significantly 
slower doubling time which became even longer after 6 passages (Malgieri et al., 2010). 
Finally, hUCBSC has lower immunogenicity and graft-versus-host reactivity when 
compared to BMSC (Malgieri et al., 2010). There are four different methods for isolation and 
purification of hUCBSC: density gradient centrifugation, flow cytometry isolation, 
attachment screening and two-step enzymatic digestion (Zhang et al., 2006). In our 
laboratory, the cord blood is subjected to fractionation on a density gradient solution, such 
as Ficoll, after which the cells are plated. Primary cultures are usually maintained for 12–16 
days, and are then detached by trypsinization and subcultured. As such, umbilical cord 
blood bank represents a rich source of multipotent stem cells that are readily available for 
transplantation or for generating diverse tissue-specific adult stem/progenitor cells and 
their further differentiated progeny for cellular therapies of various disorders in humans 
(Barrilleaux et al., 2006; Brunstein et al., 2007; Mimeault and Batra, 2006). 
Human umbilical cord blood stem cells offer great potential for novel therapeutic 
approaches targeted against many CNS diseases. The therapeutic potential of hUCBSC may 
either be attributed to the inherent ability of stem cell populations to replace damaged 
tissues outright, or alternatively, to their ability to repair damaged tissues through neural 
protection and secretion of neurotrophic factors by various cell types within the graft (Park 
et al., 2011; Sanberg et al., 2005). Previous studies have reported that hUCBSC are beneficial 
in reversing the deleterious behavioral effects of spinal cord injury, even when infused 5 
days after injury (Saporta et al., 2003). Transplanted hUCBSC differentiate into various 
neural cells and induce motor function improvement in SCI rat models (Kuh et al., 2005). 
However, to date, very few reports have utilized hUCBSC in SCI. More thorough 
experiments are needed to evaluate how hUCBSC modulates improvement after SCI and 
whether it possesses the potential of tissue plasticity (Enzmann et al., 2006). In our 
laboratory, using SCI injury model in rats, we transplanted hUCBSC one week after SCI to 
evaluate neural cell differentiation and functional improvement. We have shown that  
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hUCBSC transdifferentiated into neurons and oligodendrocytes, and downregulated Fas-
mediated apoptosis (Dasari et al.,  2007b; Dasari et al.,  2008). The hUCBSC-
transdifferentiated oligodendrocytes facilitate the secretion of neurotrophic hormones NT3 
and BDNF and synthesize MBP and PLP, promoting the remyelination of demyelinated 
axons in the injured spinal cord (Dasari et al., 2007b). Furthermore, apoptotic pathways 
mediated by both Fas and TNF-α were downregulated by hUCBSC (Dasari et al., 2008). Our 
findings confirmed that mesenchymal stem cells were able to downregulate apoptotic 
pathways mediated by Fas and Caspase-3 (Figure 2) (Dasari et al., 2007b; Dasari et al., 2008). 
In hUCBSC-treated rats, the PI3K/Akt pathway was also involved in anti-apoptotic actions. 
Further, the structural integrity of the cytoskeletal proteins α-tubulin, MAP-2A and -2B and 
NF-200 has been maintained with hUCBSC treatments. The locomotor scale scores in 
hUCBSC-treated rats were significantly improved compared to those of the injured group. 
Taken together, hUCBSC-mediated down-regulation of Fas and caspases may lead to 
functional recovery of the hind limbs of rats after SCI. With extension of this study, using 
RT-PCR microarray and analyzing 84 apoptotic genes, we identified the genes that render 
the injured spinal cord harmful and the hUCBSC-treated spinal cord conducive to 
regeneration and repair at 3 weeks (Dasari et al., 2009). We observed that the genes involved 
in inflammation and apoptosis were up-regulated (phospho-p53 and Bax) in the injured 
spinal cords of rats (Kotipatruni et al., 2011), whereas the genes involved in neuroprotection 
were up-regulated in the hUCBSC-treated rats (Dasari et al., 2008). Changes in the 
expressions of TNF-α, TNFR1 and TNFR2 were detected over 3 weeks after SCI and after 
transplantation with hUCBSC cells. The expression of P50 and P65 on neurons after SCI was 
efficiently inhibited by application of hUCBSC. Both the in vivo and in vitro studies support 
our hypothesis that the therapeutic mechanism of hUCBSC is inhibition of the neuronal 
apoptosis during the repair of injured spinal cord. Veeravalli et al. (2009a) reported the 
involvement of tissue plasminogen activator (tPA) after SCI in rats and the role of hUCB 
stem cells. The tPA expression and activity were studied in vivo after SCI in rats and in vitro 
in rat embryonic spinal neurons in response to injury with staurosporine, hydrogen 
peroxide and glutamate. The expression of tPA increased after SCI and reached peak levels  
at 3 weeks post-SCI. The MBP expression was minimal at the time of the peak tPA activity 
and vice versa. By contrast, infusion of hUCBSC stem cells down-regulated the elevated tPA 
activity in vivo in rats as well as in vitro in the spinal neurons. Further, MMP-2 is 
upregulated after hUCBSC treatment in spinal cord injured rats and in spinal neurons 
injured either with staurosporine or hydrogen peroxide. Also, hUCBSC-induced 
upregulation of MMP-2 diminished formation of the glial scar at the site of injury along with 
reduced immunoreactivity to chondroitin sulfate proteoglycans. This upregulation of MMP-
2 levels and reduction of glial scar formation by hUCBSC treatment after SCI created an 
environment more favorable for endogenous repair mechanisms (Veeravalli et al., 2009b). 
There have been an increasing number of studies suggesting that these hUCB derived-
CD34+ cells can induce angiogenesis and endo/exogenous neurogenesis in stroke (Taguchi 
et al., 2004) and SCI (Kao et al., 2008). In addition, Chen et al. (2008) recently showed that 
hUCB cells have the ability to secrete multiple neurotrophic factors. Their study 
demonstrated elevation of neuroprotective cytokine serum IL-10 levels and depression of 
TNF-α levels after hUCB cell infusion. Moreover, both GDNF and VEGF could be detected 
in the injured spinal cord after the transplantation of hUCB cells, promoting angiogenesis 
and neuronal regeneration. 
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Fig. 2. Fas expression after SCI and treatment with hUCBSC: (A) Fas immunoreactivity on 
TUNEL positive cells. Expression of Fas (Texas-red conjugated) on TUNEL positive cells 
(green) from injured sections. (B) Cryo-sections showing co-localization of Fas and NF-200 
(specific for neurons) and Fas and APC (mature marker for oligodendrocytes) showing 
expression of Fas on neurons and oligodendrocytes (↑) undergoing apoptosis. Fas is FITC-
conjugated and NF-200 and APC are Texas-red conjugated. Results are from 3 sections 
between 1 and 2mm caudal to the injury epicenter after 3 weeks SCI (n≥3). (C) Confocal 
images of cryo-sections illustrate co-localization (yellow) of activated caspase-3 (FITC-
conjugated) with NF-200 (Texas-red conjugated) and APC (Texas-red conjugated) within the 
dorsal region(↑), following spinal cord contusion. For panels A, B and C Bar = 100μm.  
(D) Top panel shows BBB scores of rats with SCI before and after hUCB transplantation. 
Repeated-measures of ANOVA followed by Bonferroni’s post hoc tests showed that BBB 
scores in hUCB-grafted animals were significantly higher than those in injured-untreated 
animals. Each point represents the highest locomotor score achieved each day. Middle panel 
shows Narrow beam scores of injured and treated rats over a period of 6 weeks and bottom 
panel shows number of placing responses of injured and treated animals. Arrow (↓) indicates 
hUCB transplantation point. Error bars indicate ±SEM (n≥5/group) (*p<0.01 and **p<0.05) 
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4. Conclusions 
Transplantation of mesenchymal stem cells into the injured spinal cord and therapeutic 
applications of mesenchymal stem cells represent exciting new approaches to managing 
spinal cord injury. Improvements in molecular techniques and strategies along with the 
availability of modified stem cell lines have fostered our understanding in the mechanism of 
SCI and advanced the application of stem cell transplantation for treatment of other 
neurological disorders beyond traumatic brain and spinal cord injury. However, cell-based 
therapy for SCI is still at an early stage and faces numerous challenges: among them safety 
problem, patient’s genetic diversity and variability, differences in the extent of injury, 
translational clinical issues, regulatory and ethical concerns. There are numerous ongoing 
clinical trials utilizing MSC transplantation for treatment of various genetic and neurological 
disorders. However, the ultimate value of cell-based therapy will need continued expansion 
of basic scientific knowledge of disease processes and proven therapeutic efficacy via 
rigorous controlled, randomized, double blind clinical trials. 
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